• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    antibodies to matrix metalloproteinase 9. The present invention relates to compositions and methods of use involving binding proteins, for example antibodies and antigen binding fragments thereof, which bind to matrix metalloproteinase 9 (mmp9) protein (mmp9 is also known as gelatinase- b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).
    公开号:BR112013004579B1
    申请号:R112013004579-5
    申请日:2011-08-26
    公开日:2019-03-12
    发明作者:Scott Alan McCauley；Maria Vaysberg
    申请人:Gilead Biologics, Inc.；
    IPC主号:
    专利说明:

    Invention Patent Descriptive Report for “MONOCLONAL ANTIBODY, NUCLEIC ACIDS, VECTOR, TRANSGENIC MICROORGANISM, PHARMACEUTICAL COMPOSITION, MMP9 EXPRESSION DETECTION METHOD, AND, USE OF PHARMACEUTICAL COMPOSITION”. CROSS REFERENCE TO RELATED PATENT APPLICATIONS
    This patent application claims the priority benefit of U.S. provisional patent application No. Serial 61 / 377,886, filed on August 27, 2010, which patent application is incorporated into this application by reference in its entirety.
    FIELD
    This description is in the field of extracellular enzymes, extracellular matrix enzymes, proteases and immunology.
    INTRODUCTION
    Matrix metalloproteinases (MMPs) are a family of extracellular enzymes involved in the formation and remodeling of the extracellular matrix. These enzymes contain a conserved catalytic domain in which a zinc atom is coordinated by three histidine residues. Currently, more than 20 members of this family are known, organized into several groups including collagenases, gelatinases, stromelysins, matrilisins, enamelisins and membrane MMPs.
    MMP2 and MMP9 belong to the matrix metalloproteinase gelatinase group. In addition to containing the signal peptide, pro-peptide, zinc-binding and hemopexin-like catalytic domains common to most MMPs, gelatinases also contain a plurality of fibronectin-like domains and an O-glycosylated domain.
    Abnormal activity of certain MMPs has been shown to play a role in tumor growth, metastasis, inflammation and vascular disease. See, for example, Hu et al. (2007) Nature Reviews: Drug Discovery 6: 480-498. Because of this, it may be desirable to inhibit the activity of one or more MMPs in certain therapeutic settings. However, the activity of other MMPs is often necessary for normal function. Since the majority of MMP inhibitors are directed to the conserved catalytic domain and, as a result, inhibit several different MMPS, their use will have thereafter 870180167211, of 12/24/2018, p. 12/52
    2/36 pharmaceuticals caused side effects due to the inhibition of essential MMPs, not pathogenically reported.
    Despite this problem, it has been proven difficult to develop inhibitors that are specific to a particular MMP, because inhibition of enzyme activity generally requires that the inhibitor be targeted to the catalytic domain. Consequently, most inhibitors of enzyme activity of matrix metalloproteinase are likely to react with more than one MMP, due to homology in their catalytic domains. Thus, there remains a need for therapeutic reagents that specifically inhibit the catalytic activity of a single MMP, and that do not react with other MMPs.
    SUMMARY
    The present description provides compositions and methods of use involving binding proteins, for example, antibodies and antigen-binding fragments thereof, which bind to the matrix metalloproteinase 9 (MMP9) protein (MMP9 is also known as gelatinase-B) , wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). The description further provides binding proteins to MMP9 that specifically bind to MMP9 and not to other related matrix metalloproteinases. The binding proteins of such MMP9 find use in applications in which it is necessary or desirable to obtain the specific modulation (for example, inhibition) of MMP9, for example, without directly affecting the activity of the other matrix metalloproteinases. Thus, in certain embodiments of the present description, an antiMMP9 antibody is a specific inhibitor of MMP9 activity. In particular, MMP9 binding proteins described in this application will be useful for inhibiting MMP9 allowing normal function of other related matrix metalloproteinases.
    Consequently, the present description provides, interalia.
    1. An MMP9-binding protein comprising an immunoglobulin heavy chain or functional fragment thereof, and an
    3/36 immunoglobulin light chain or functional fragment thereof, in which the protein does not bind to a matrix metalloproteinase other than MMP9.
    2. The protein according to modality 1, where the heavy chain comprises a complementarity determining region (CDR) selected from one or more of SEQ ID NOS: 13-15, and the light chain comprises a selected CDR from one or more of SEQ ID NOS: 16-18.
    3. The protein according to modality 2, where the heavy chain comprises a variable region selected from the group consisting of SEQ ID NOS: 3 or 5-8, and the light chain comprises a variable region selected from the group consisting of SEQ ID NOS: 4 or 912.
    4. The protein according to modality 1, where the heavy chain is IgG.
    5. The protein according to modality 1, where the light chain is a kappa chain.
    6. The protein according to modality 1, in which the binding of the protein to MMP9 inhibits the enzymatic activity of MMP9.
    7. The protein according to modality 6, in which the inhibition is non-competitive.
    8. The protein according to modality 1, wherein the heavy chain is encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 19-22 and the light chain is encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 23-26.
    9. A vector comprising one or more polynucleotides having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 19-26.
    10. A cell comprising the vector according to mode 9.
    11. A pharmaceutical composition comprising the protein according to modality 1.
    4/36
    12. A pharmaceutical composition comprising the vector according to modality 9.
    13. A pharmaceutical composition comprising the cell according to embodiment 10.
    BRIEF DESCRIPTION OF THE DRAWINGS
    Figure 1 shows the amino acid sequence of the variable region of the heavy chain of a mouse anti-MMP9 monoclonal antibody (ABO041), along with the amino acid sequences of humanized heavy chain variants (VH1-VH4), aligned to show differences in amino acid sequence of conserved region that results from humanization. The CDRs are shown in italics, and the amino acids that are different in the humanized variants, compared to the parent mouse monoclonal, are underlined.
    Figure 2 shows the amino acid sequence of the variable region of the light chain of a mouse anti-MMP9 monoclonal antibody (AB0041), along with the amino acid sequences of humanized variants of this light chain (VH1-VH4), aligned to show differences in amino acid sequence of the conserved region that results from humanization. CDRs are shown in italics, and amino acids that are different in humanized variants, compared to the parent mouse monoclonal, are underlined.
    Figure 3 shows a schematic diagram of the MMP9 protein.
    DETAILED DESCRIPTION
    The practice of the present description employs, unless otherwise indicated, standard methods and conventional techniques in the fields of cytology, toxicology, molecular biology, biochemistry, cell culture, immunology, oncology, recombinant DNA and related fields as are within the skill of the technique. Such techniques are described in the literature and hereby available to those skilled in the art. See, for example, Alberts, B. et al, Molecular Biology of the Cell, 5th edition, Garland Science, New York, NY . , 2008; Voet, D. et al. Fundamentals of Biochemis5 / 36 try: Life at the Molecular took me, 3rd edition, John Wiley & Sons, Hoboken, NJ, 2008; Sambrook, J. et al, Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press . , 2001; Ausubel, F. et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987 and periodic updates; Freshney, RI, Culture of Animal Cells: A Manual of Basic Technique, 4th edition, John Wiley & Sons, Somerset, NJ, 2000; and the Methods in Enzimology Academic Press series, San Diego, CA.
    Also see, for example, Current Protocols in Immunology, (R. Coico, series editor), Wiley, last updated in August 2010.
    MIVIP9 binding proteins
    The present description provides binding proteins, for example, antibodies and antigen-binding fragments thereof, which bind to the matrix metalloproteinase 9 (MMP9) protein (MMP9 is also known as gelatinase-B). description generally comprises an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    The description further provides MMP9 binding proteins that specifically bind MMP9 and not other matrix metalloproteinases such as MMP1, MMP2, MMP3, MMP7, MMP9, MMP10, MMP12, MMP13. Such specific MMP9 binding proteins in this manner are generally not significantly or detectably cross-reactive with non-MMP9 matrix metalloproteinases. MMP9 binding proteins that specifically bind MMP9 find use in applications in which it is necessary or desirable to obtain specific modulation (for example, inhibition) of MMP9, for example, without directly affecting the activity of other matrix metalloproteinases.
    In certain embodiments of the present description, an antiMMP9 antibody is an inhibitor of MMP9 activity and can be a specific inhibitor of MMP9. In particular, the MMP9-binding proteins described in this application will be useful for inhibiting MMP9 allowing normal function of
    6/36 other related matrix metalloproteinases. An MMP inhibitor or inhibitor of MMP9 activity can be an antibody or antigen-binding fragment thereof that directly or indirectly inhibits MMP9 activity, including but not limited to enzymatic processing, inhibiting the action of MMP9 on its substrate ( for example, inhibiting substrate binding, substrate divage and the like), and the like.
    The present description also provides MMP9 binding proteins that specifically bind to non-mouse MMP9, such as human MMP9, cinomolgus monkey MMP9 and mouse MMP9.
    The present description also provides MMP9 binding proteins (for example, anti-MMP9 antibodies and functional fragments thereof) that act as non-competitive inhibitors. A non-competitive inhibitor refers to an inhibitor that binds at the site away from the substrate binding site of an enzyme, and thus can bind to the enzyme and affect the inhibitory activity whether or not the enzyme is bound to its substrate. Such non-competitive inhibitors, for example, can provide a level of inhibition that can be substantially independent of the substrate concentration.
    The MMP9-binding proteins (e.g., antibodies and functional fragments thereof) of the present description include those that bind to MMP9, particularly human MMP9 and having a heavy chain polypeptide (or functional fragment thereof) having at least approximately 80 %, 85%, 90%, 95% or more amino acid sequence identity to a heavy chain polypeptide described in this application.
    The MMP9-binding proteins (e.g., antibodies and functional fragments thereof) of the present description include those that bind to MMP9, particularly human MMP9 and having a light polypeptide (or functional fragment thereof) having at least approximately 80%, 85%, 90%, 95% or more amino acid sequence identity to a heavy chain polypeptide described in this application.
    The MMP9-binding proteins (for example, antibodies and functional fragments thereof) of the present description include those
    7/36 that bind to MMP9, particularly human MMP9, and have a heavy chain polypeptide (or functional fragment thereof) having the complementarity determining regions (CDRs) of the heavy chain polypeptide and the CDRs of a polypeptide in the chain light weight (or functional fragment thereof) as described in this application.
    Homology or identity or similarity as used in this application in the context of nucleic acids and polypeptides refers to the relationship between two polypeptides or two nucleic acid molecules based on an alignment of the amino acid sequences or nucleic acid sequences, respectively. Homology and identity can each be determined by comparing a position in each sequence that can be aligned for comparison purposes. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical in that position; when the equivalent site occupied by the same or similar amino acid residue (for example, similar in steric and / or electronic nature), then the molecules can be said to be homologous (similar) in that position. The expression as a percentage of homology / similarity or identity refers to a function of the number of identical or similar amino acids in positions shared by the compared sequences. When comparing two sequences, the absence of residues (amino acids or nucleic acids) or the presence of extra residues also reduces the identity and homology / similarity.
    As used in this application, identity means the percentage of identical nucleotide or amino acid residues in corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, that is, considering gaps and insertions. The sequences are generally aligned with maximum matching over a designated region, for example, a region of at least approximately 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or more amino acids or nucleotides in length, and may be up to the length of the complete reference amino acid or nucleotide. For sequence comparison, typically a sequence acts as a reference sequence, with which the test sequences are compared. Using a sequence comparison algorithm, the test and reference sequences are entered into a computer program, the subsequence coordinates are designated, if necessary, and the parameters of the sequence algorithm program are designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence (s) in relation to the reference sequence, based on the designated program parameters.
    Examples of algorithms that are suitable for determining percent sequence identity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively. The BLAST analysis program is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). Other exemplary algorithms include ClustalW (Higgins D., et al. (1994) Nucleic Acids Res. 22: 4673-4680), available at www.ebi.ac.uk/Tools/clustalw/index.html.
    Residue positions that are not identical can be differentiated by conservative amino acid substitutions. Conservative amino acid substitutions refer to the exchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine and isoleucine; a group of amino acids having aliphatic and hydroxyl side chains is serine and threonine; a group of amino acids having side chains containing amide is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine and tryptophan; a group of amino acids having basic side chains is lysine, arginine and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine.
    The sequence identity between two nucleic acids can also be described regarding the hybridization of two molecules to each other under stringent conditions. Hybridization conditions are selected using standard methods in the art (see, for example, Sambrook, et al., Molecular
    9/36
    Cloning: A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.). An example of stringent hybridization conditions is hybridization at 50 ° C or more and 0.1 x SSC (15 mM sodium chloride / 1.5 mM sodium citrate). Another example of stringent hybridization conditions is the night incubation at 42 ° C in a solution: 50% formamide, 5 x SSC (150 mM NaCI, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), solution Denhardt 5 x, 10% dextran sulphate and 20 mg / ml denatured salmon sperm DNA, followed by washing the filters in 0.1 χ SSC at approximately 65 ° C. Stringent hybridization conditions are hybridization conditions that are at least as stringent as the representative conditions above, where conditions are considered to be at least as stringent if they are at least approximately 80% as stringent, typically at least 90% as stringent as specific stringent conditions above.
    Accordingly, the present description provides, for example, antibodies or antigen-binding fragments thereof, comprising a heavy chain variable region polypeptide having at least 80%, 85%, 90%, 95% or greater amino acid sequence identity an amino acid sequence of a variable region of the heavy chain described in this application (for example, SEQ ID NOS: 1 or 5-8), and a variable light chain polypeptide having at least 80%, 85%, 90%, 95 %, or greater amino acid sequence identity to an amino acid sequence of a light chain polypeptide as presented in this application (for example, SEQ ID NOS: 2 or 9-12).
    The examples of anti-MMP9 antibodies of the present description are described in more detail below.
    Antibodies.
    MMP9-binding proteins including antibodies and functional fragments thereof. As used in this application, the term antibody means an isolated polypeptide or recombinant binding agent that comprises peptide sequences (e.g., variable region sequences) that specifically bind to an antigenic epitope. The term is used10 / 36 do in its broadest sense and specifically covers monoclonal antibodies (including complete monoclonal antibodies), polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, nanobodies, diabody, multispecific antibodies (eg bispecific antibodies), and antibody fragments including but not limited to Fv, scFv, Fab, Fab 'F (ab') 2 and Fab2, as long as they exhibit the desired biological activity. The term human antibody refers to antibodies that contain sequences of human origin, except for possible non-human CDR regions, and does not imply that the complete structure of an immunoglobulin molecule is present, only that the antibody has the minimum immunogenic effect in a human being (that is, the production of antibodies is not induced).
    An antibody fragment comprises a portion of an entire antibody, for example, the antigen binding or variable region of a whole body antibody. Such antibody fragments can also be referred to in this application as functional fragments: or antigen-binding fragments. Examples of antibody fragments include Fab, Fab ', F (ab') 2, and Fv fragments; diabodies; linear antibodies (Zapata et al. (1995) Protein Eng. 8 (10): 1057-1062); single chain antibody molecules; and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called Fab fragments, each with a unique antigen-binding site and a residual Fc fragment, a designation that reflects the ability to readily crystallize. Treatment with pepsin produces an F (ab ') 2 fragment that has two antigen combining sites and is still capable of interconnecting with the antigen.
    Fv is the minimum antibody fragment that contains a complete and binding antigen recognition site. This region consists of a dimer of a variable domain of the heavy chain and one of the light in close association, not covalent. It is in this configuration that the three complementarity determining regions (CDRs) of each variable domain interact to define an antigen-binding site on the surface of the Vh-Vl dimer. Collectively, the six CDRs confer specificity of connection to the
    11/36 antigen to the antibody. However, even a single variable domain (or an isolated Vh or V l region comprising only three of the six antigen-specific CDRs) has the ability to recognize and bind to the antigen, although generally at a lower affinity than the frag5 F v integer.
    The F a b fragment also contains, in addition to variable regions of the heavy and light chain, the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments were originally observed after papain digestion of an antibody. Fab 'fragments differ from Fab fragments in which F (ab') fragments contain several additional residues in the terminal carboxy of the CH1 domain of the heavy chain, including one or more cysteines from the antibody hinge region. F (ab ') 2 fragments contain two Fab fragments together, close to the hinge region, by disulfide bonds, and were originally observed after digestion with an antibody with pepsin. Fab'-SH is the designation in this application for Fab 'fragments in which the cysteine residue (s) of the constant domains carry a free thiol group. Other chemical couplings of antibody fragments are also known.
    The light chains of antibodies (immunoglobulins) of any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to five main classes: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), for example, lgG1, lgG2, lgG3, lgG4, lgA1 and lgA2.
    Fragments of single chain Fv antibody or scFv or sFv comprise the Vh and Vl domains of the antibody, where these domains are present in a single polypeptide chain. In some ways, the Fv polypeptide further comprises a polypeptide linker between the Vh and Vl domains, which allows the sFv to form the desired antigen binding structure. For a review of sFv, see Pluckthun, in The Phar12 / 36 macology of Monoclonal Antibodies, volume 113 (Rosenburg and Moore eds.) Springer-Verlag, New York, pp. 269-315 (1994).
    The term diabody refers to small antibody fragments with two antigen-binding sites, fragments which comprise a heavy chain variable domain (VH) joined to a light chain variable domain (VL) on the same polypeptide chain (V H -V L ). By using a linker that is too short to allow pairing between the two domains in the same chain, the domains are forced to pair with the complementary domains of another chain, thereby creating two antigen-binding sites. Diabodies are further described, for example, in EP 404,097; WO 93/11161 and Hollinger et al. (1993) Proc. Natl. Acad. Know. USA 90: 6444-6448.
    An isolated antibody is one that has been identified and separated and / or recovered from a component of its environment. The components of your environment can include enzymes, hormones and other protein or non-protein solutes. In some embodiments, an isolated antibody is purified (1) to more than 95% by weight of the antibody as determined by the Lowry method, for example, more than 99% by weight, (2) to a degree sufficient to obtain at least 15 N-terminal residues or internal amino acid sequence, for example, by using a rotating cup sequencer, or (3) homogeneity by gel electrophoresis (for example, SDS-PAGE) under reducing or non-reducing conditions, with detection by Coomassie blue or silver marking. The term antibody isolated includes an antibody in situ within recombinant cells, since at least one component of the antibody environment will not be present. In certain embodiments, the isolated antibody is prepared by at least one purification step.
    As used in this application, immunoreactive refers to antibodies or fragments thereof that are specific to a sequence of amino acid residues (binding site or epitope), even if they are cross-reactive to other peptides / proteins, they are not toxic at levels at which are formulated for administration for human use. Epitope refers to 13/36 if that portion of an antigen capable of forming a binding interaction with an antibody or antigen-binding fragment thereof. An epitope can be a linear (i.e., continuous) peptide sequence or it can be composed of non-contiguous (i.e., conformational or discontinuous) amino acid sequences. The term preferably binds means that the binding agent binds to the binding site with greater affinity than it binds to unrelated amino acid sequences.
    Anti-MMP9 antibodies can be described in terms of heavy and light chain CDRs. As used in this application, the term CDR or complementarity determining region is intended to be understood by non-contiguous antigen combining sites found within the variable region of both heavy chain and light chain polypeptides. These particular regions have been described by Kabat et al., J. Biol. Chem. 252: 6609-6616 (1977); Kabat et al., U.S. Dept. of Health and Human Services, Sequences of proteins of immunological interest (1991); by Chothia et al., J. Mol. Biol. 196: 901-917 (1987); and MacCallum et al., J. Mol. Biol. 262: 732-745 (1996), where definitions include overlap or subsets of amino acid residues when compared to each other. However, the application of the definition to refer to a CDR of an antibody or of grafted antibodies or variants thereof is intended to be within the scope of the term as defined and used in this application. The amino acid residues that comprise the CDRs as defined by each of the references cited above are shown below in Table 1 as a comparison.
    Table 1: CDR definitions
    Kabat 1 Chothia 2 MacCailum 3
    V H CDR1 31-35 26-32 30-35 V H CDR2 50-65 53-55 47-58 V H CDR3 95-102 96-101 93-101 CDR1 of V L 24-34 26-32 30-36 CDR2 of V L 50-56 50-52 46-55 CDR3 of V L 89-97 91-96 89-96
    14/36 1 Residue numbering follows the nomenclature of Kabat etal., Supra 2 Residue numbering follows the nomenclature of Chothia et al., Supra 3 Residue numbering follows the nomenclature of MacCalIum et al., Supra
    As used in this application, the term conserved region when used in reference to an antibody variable region is intended to mean all amino acid residues outside the CDR regions within an antibody variable region. A conserved region of variable region is generally a discontinuous amino acid sequence between approximately 100-120 amino acids in length but is intended for reference only those amino acids outside the CDRs. As used in this application, the term conserved region is intended to mean each domain of the conserved region that is separated by the CDRs.
    In some embodiments, an antibody is a humanized antibody or a human antibody. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. Thus, the humanized forms of non-human antibodies (for example, murines) are chimeric immunoglobulins that contain the minimal sequence derived from non-human immunoglobulin. Non-human sequences are located mainly in the variable regions, particularly in the complementarity determining regions (CDRs). In some embodiments, residues from the conserved Fv region of human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues that are found neither in the recipient's antibody nor in the imported CDR or conserved region sequences. In certain embodiments, a humanized antibody comprises substantially all of at least one and typically two variable domains, in which all or substantially all CDRs correspond to those of a non-human immunoglobulin and all or substantially all of the regions
    Conserved 15/36 are those from a consensus human immunoglobulin sequence. For the purposes of the present description, humanized antibodies may also include fragments of immunoglobulin, such as Fv, Fab, Fab ', F (ab') 2 or other antigen-binding substrates of antibodies.
    The humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. See, for example, Jones et al. (1986) Nature 321: 522-525; Riechmann et al. (1988) Nature 332: 323-329; and Presta (1992) Curr. Op. Struct. Biol. 2: 593-596.
    Methods for humanizing non-human antibodies are known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as import or donor residues, which are typically obtained from a donor or import variable domain. For example, humanization can be performed essentially according to the method of Winter and collaborators, substituting rodent CDRs or CDR sequences from the corresponding sequences of a human antibody. See, for example, Jones et al., Supra, Riechmann et al., Supra and Verhoeyen et al. (1988) Science 239: 1534-1536. Consequently, such humanized antibodies include chimeric antibodies (U.S. Patent No. 4,816,567), in which substantially less than an intact human variable domain has been replaced by the corresponding sequence from a non-human species. In certain embodiments, humanized antibodies are human antibodies in which some CDR residues and optionally some conserved region residues are replaced by residues from sites analogous to rodent antibodies (for example, murine monoclonal antibodies).
    Human antibodies can also be produced, for example, using phage display libraries. Hoogenboom et al. (1991) J. Mol. Biol, 227: 381; Marks et al. (1991) J. Mol. Biol. 222: 581. Other methods for preparing human monoclonal antibodies are described by
    16/36
    Cole et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 and Boerner et al. (1991) J. Immunol. 147: 86-95.
    Human antibodies can be made by introducing human immunoglobulin loci into transgenic animals (for example, mice) in which the endogenous immunoglobulin genes have been partially or completely inactivated. In the immunological challenge, human antibody production is observed, which closely resembles that seen in humans from all points of view, including gene rearrangement, antibody assembly and repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al. (1992) Bio / Technology 10: 779-783 (1992); Lonberg et al. (1994) Nature 368: 856-859; Morrison (1994) Nature 368: 812-813; Fishwald et al. (1996) Nature Biotechnology 14: 845-851; Neuberger (1996) Nature Biotechnology 14: 826; and Lonberg etal. (1995) Intem. Rev. Immunol. 13: 65-93.
    Antibodies can be affinity matured using known methods of selection and / or mutagenesis as described above. In some embodiments, affinity matured antibodies have an affinity that is five times or more, ten times or more, twenty times or more, or thirty times or more than that of the initial antibody (usually murine, rabbit, chicken, humanized or human) ) from which the matured antibody is prepared.
    An antibody can also be a bispecific antibody. Bispecific antibodies are monoclonal, and can be human or humanized antibodies that have binding specificities for at least two different antigens. In the present case, two different binding specificities can be directed to two different MMPs, or to two different epitopes in a single MMP (for example, MMP9).
    An antibody as described in this application can also be an immunoconjugate. Such immunoconjugates comprise an antibody (e.g., MMP9) conjugated to a second molecule, such as a reporter. An immunoconjugate can also comprise an antibody conjugated to
    17/36 a cytotoxic agent such as a chemotherapeutic agent, a toxin (for example, an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
    An antibody that specifically binds to or is specific to a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope without substantially binding to any other polypeptide or polypeptide epitope. In some embodiments, an antibody of the present description specifically binds to human MMP9 with a dissociation constant (Kd) of 100 nM or less, optionally less than 10 nM, optionally less than 1 nM, optionally less than 0.5 nM, optionally less than 0.1 nM, optionally less than 0.01 nM, or optionally less than 0.005 nM; in the form of monoclonal antibody, scFv, Fab or other form of antibody measured at a temperature of approximately 4 ° C, 25 ° C, 37 ° C or 42 ° C.
    In certain embodiments, an antibody of the present description binds to one or more processing sites (for example, proteolytic dividing sites) in MMP9, thereby effectively blocking the processing of the pro-enzyme or pre-pro-enzyme to the enzyme catalytically active, thereby reducing the proteolytic activity of MMP9.
    In certain embodiments, an antibody according to the present description binds to MMP9 with an affinity at least 2 times, at least 5 times, at least 10 times, at least 25 times, at least 50 times, at least 100 times, at least 500 times, or at least 1000 times greater than your binding affinity for another MMP. The binding affinity can be measured by any method known in the art and can be expressed as, for example, association rate, dissociation rate, dissociation constant (Kd), equilibrium constant (Keq) or any term in the art.
    In certain embodiments, an antibody according to the present description is a non-competing inhibitor of the catalytic activity of MMP9.
    18/36
    In certain embodiments, an antibody according to the present description binds to the catalytic domain of MMP9. In additional embodiments, an antibody according to the present description binds outside the catalytic domain of MMP9.
    The present description also contemplates antibodies or antigen-binding fragments thereof, which compete with antiMMP9 antibodies or antigen-binding fragments thereof described in this application to bind MMP9. Accordingly, the present description contemplates anti-MMP9 antibodies and functional fragments thereof, which compete for binding with, for example, an antibody having a heavy chain polypeptide of any of SEQ ID NOS; 1 or 5-8, a light chain polypeptide of SEQ ID NOS: 2 or 9-12, or combinations thereof. In one embodiment, the anti-MMP9 antibody, for the functional fragment thereof, competes for binding to human MMP9 with the antibody described in this application as AB0041.
    MMP9 string
    The amino acid sequence of the human MMP9 protein is as follows:
    MSLWQPLVLV LLVLGCCFAA PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY 50 RYGYTRVAEM RGESKSLGPA LLLLQKQLSL PETGELDSAT LKAMRTPRCG 100 VPDLGRFQTF EGDLKWHHHN ITYWIQNYSE DLPRAVIDDA FARAFALWSA 150 VTPLTFTRVY SRDADIVIQF GVAEHGEÇYP FDGKDGLLAH AFPPGPGIQG 200 DAHFDDDELW SLGKGVWPT RFGNADGAAC HFPFIFEGRS YSACTTDGRS 250 DGLPWCSTTA NYDTDDRFGF CPSERLYTRD GNADGKPCQF PFIFQGQSYS 30Q ACTTDGRSDG YRWCATTANY DRDKLFGFCP TRAD $ TVMGG C $ AGELCVFP 350 FTFLGKEYST CTSEGRGDGR LWCATTSNFD SDKKWGFCPD QGYSLFLVAA 400 HEFGHALGLD HSSVPEALMY PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE 450 PRPPTTTTPQ PTAPPTVCPT GPPTVHPSER PTAGPTGPPS AGPTGPPTAG 500 PSTATTVPLS PVDDACNVNI FDAIAEIGNQ LYLFKDGKYW RFSEGRGSRP 550 QGPFLIADKW PALPRKLDSV FEEPLSKKLF FFSGRQVWVY TGASVLGPRR 600 LDKLGLGADV AQVTGALRSG RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV 650 DRMFPGVPLD THDVFQYREK AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD ILQCPED 700 (SEQ ID NO: 27)
    The protein domains are shown schematically in Figure 3 and are indicated below:
    Amino acid # Attribute 1-19 Sign peptide 38-98 Peptidoglycan Binding Domain R98 / C99 Pro-peptide dividing site (enzyme dependent
    19/36
    divage) 112-445 Zn-dependent metalloproteinase domain 223-271 Type II fibronectin domain (gelatin binding domain) 281-329 Type II fibronectin domain (gelatin binding domain) 340-388 Type II fibronectin domain (gelatin binding domain) 400-411 Zn binding region 521-565 Domain similar to Hemopexin 567-608 Domain similar to Hemopexin 613-659 Domain similar to Hemopexin 661-704 Domain similar to Hemopexin
    The amino acid sequence of mature whole human MMP9 (which is the amino acid sequence of the pro-polypeptide of SEQ ID NO: 27 without the signal peptide) is:
    PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY RYGYTRVAEM RGESKSLGPA
    LLLLQKQLSL PETGELDSAT LKAMRTPRCG VPDLGRFQTF EGDLKWHHHN
    ITYWIQNYSE DLPRAVIDDA FARAFA1WSA VTPLTFTRVY SRDADIVIQF
    GVAEHGDGYP FDGKDGLLAH AFPPGPGIQG DAHFDDDELW SLGKGWVPT
    RFGNADGAAC HFPFIFEGRS YSACTTDGRS DGLPWCSTTA NYDTDDRFGF
    CPSERLYTRD GNADGKPCQF PFIFQGQSYS ACTTDGRSDG YRWCATTANY
    DRDKLFGFCP TRADSTVMGG NSAGELCVFP FTF1GKEYST CTSEGRGDGR
    LWCATTSNFD SDKKWGFCPD QGYSLFLVAA HEFGHALGLD HSSVPEALMY
    PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE PRPPTTTTPQ PTAPPTVCPT
    GPPTVHPSER PTAGPTGPPS AGPTGPPTAG PSTATTVPLS PVDDACNVNI
    FDAIAEIGNQ LYLFKDGKYW RFSEGRGSRP QGPFLIADKW PALPRKLDSV
    FEEPLSKKXF FFSGRQVWVY TGASVLGPRR LDKLGLGADV AQVTGALRSG
    RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV DRMFPGVPLD THDVFQYREK
    AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD ILQCPED (SEQ ID NO: 28) where the amino acid sequence of the signal peptide is MSLWQPLVLV LLVLGCCFAA (SEQ ID NO: 29).
    The present description contemplates MMP9 binding proteins that bind to any portion of MMP9, for example, human MMP9, with MMP9 binding proteins that preferentially bind MMP9 over other MMPs being of special interest.
    Anti-MMP9 antibodies and functional fragments thereof can be generated accordingly by well-known methods
    20/36 in the art. Examples of anti-MMP9 antibodies are provided below.
    Monoclonal anti-mouse MMP9
    A mouse monoclonal antibody to human MMP9 was obtained as described in Example 1. This antibody contains a mouse IgG2b heavy chain and a mouse kappa light chain, and is denoted AB0041.
    The amino acid sequence of the AB0041 heavy chain is as follows:
    MAVLVLFLCLVAFPSCVLSOVOLKESGPGLVAPSOSLSITCTVSGFSLLSYGVHW VRQPPGKGLEWLGVIWTGGTTNYNSALMSRLSISKDDSKSQVFLKMNSLQTDDTAIYY CARYYYGMDYWGQGTSVTVSSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTV TWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPIS TINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCWVDVSEDDPDVR1SWF VNNVEVUTAQTQTHREDYNSTIRVVSALPlQHQDWMSGKEFKCKVNNKDLPSPIERnSKIKG LVRAPQVYILPPPAEQLSRKDVSLTCLWGFNPGDISVEWTSNGHTEENYKDTAPVLDSDGSY FIYSKLDIKTSKWEKTDSFSCNVRHEGLKNYYLKKT1SRSPGK (SEQ ID NO: 1)
    The signal sequence is underlined, and the sequence of the constant region lgG2b is shown in italics.
    The amino acid sequence of the AB0041 light chain is as follows:
    MESOIOVFVFVFLWLSGVDGDIVMTQSHKFMSTSVGDRVSITCKASQDVRNTVA WYQQKTGQSPKLLrYSSSYRNTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYFCQQHYrr PYYPGGGTKLEYKRADAAPTVSIFPPSSEQLTSGGASWCFLNNFYPKDINVKWKIDGSERQN GVLNSWTDQDSKDSTYSMSSTLTETKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 2)
    The signal sequence is underlined, and the sequence of the kappa constant region is shown in italics.
    The following amino acid sequence comprises the conserved regions and complementarity determining regions (CDRs) of the AB0041 lgG2b heavy chain variable region (with the CDRs underlined):
    OVOLKESGPGLVAPSOSLSITCWSGFSLLSYGVIfWVROPPGKGLEWLGVIWTGGTTN YNSAI ^ MSRLSISKDDSKSOVFLKMNSLOTDDTAIYYCARYYYGMDYWGOGTSVTVSS (SEQ ID NO: 3)
    The following amino acid sequence comprises the regions
    21/36 conserved and complementarity determination regions (CDRs) of the AB0041 kappa light chain variable region (with CDRs underlined):
    DIVMTOSHKFMSTSVGDRVSITCKASODVRNTVAWYQOKTGOSPKLIJYSSSYRNTGV PDRFTGSGSGTDFTFTrSSVOAEDIAVYFCOOHYITPYTFGGGTKLEIK (SEQ ID NO: 4)
    Heavy chain variants
    The amino acid sequences of the variable regions of the heavy and light chains of AB0041 were separately modified, altering sequences of the conserved region in the variable regions of the heavy and light chains. The effect of these sequence changes was to deplete the antibody from human T cell epitopes, thereby reducing or eliminating their immunogenicity in humans (Antitope, Babraham, United Kingdom).
    Four variants of the heavy chain were constructed, in the context of the human IgG4 heavy chain containing an amino acid modification S241P that stabilizes the hinge domain (Angal et al. (1993) Molec. Immunol. 30: 105-108), and are denoted VH1, VH2, VH3 and 15 VH4. The amino acid sequences of its conserved regions and CDRs are as follows;
    VH1
    QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTG GTTNYNSALMSRI.TISKDDSKSTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTSV TVSS (SEQIDNO: 5)
    VH2 QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGV1IWVRQPPGKGLEWLGVIWTG GTTNYNSALMSRLTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLV TVSS (SEQIDNO): SEQIDNO
    VH3
    QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTG GTTNYNSALMSRFnSKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLV TVSS (SEQIDNO: 7)
    VH4
    QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTG GTTNYNSALMSRFnSKDDSKNTLYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLV TVSS (SEQIDNO:)
    22/36
    Figure 1 shows an alignment of the amino acid sequences of the variable regions of the humanized heavy chains and indicates the differences in amino acid sequences in the conserved regions between the four variants.
    Light chain variants
    Four variants of the light chain were built, in the context of the human kappa chain, and are denoted Vk1, Vk2, Vk3 and Vk4. The amino acid sequences of its conserved regions and CDRs are as follows:
    Vkl DIVMTQSPSFLSASVGDRVTnOKASQDVRNTVAWYQQKTGKAPKLLIYSSSYR NTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYPCQQHYITPYTPGGGTKVEIK (SEQ ID NO: 9)
    Vk2 DIVMTQSPSSLSASVGDRVnTCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYR NTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYFCQQHYITPYTFGGGTKVEIK (SEQ ID NO: 10)
    Vk3 DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYR NTGVPDRFSGSGSGTOFTLTlSSLQAEDVAVYFCQQHYrrPYTFGGGTKVEIK (SEQ ID NO: 11)
    Vk4
    DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYR NTGVPDRFSGSGSGTOFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK (SEQ ID NO: 12)
    Figure 2 shows an alignment of the amino acid sequences of the variable regions of the humanized light chains and indicates the differences in amino acid sequences in the conserved regions between the four variants.
    Heavy and light humanized chains are combined in all of the possible paired combinations to generate several functionalized humanized antiMMP9 antibodies.
    Additional heavy chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more or 99% or more homology to the heavy chain variable region sequences
    23/36 described in this application are also provided. In addition, additional light chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more or 99% or more homology to the light chain variable region sequences described in this application are also provided.
    Additional heavy chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more or 99% or more sequence identity to the heavy chain variable region sequences described in this application as well are provided. In addition, additional light chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more or 99% or more sequence identity to the light chain variable region sequences described in this application are also provided.
    Complementarity determination regions (CDRs)
    The heavy chain CDRs of an anti-MMP9 antibody as described in this application have the following amino acid sequences:
    CDR1: GFSLLSYGVH (SEQ ID NO: 13)
    CDR2: VIWTGGTTNYNSALMS (SEQ ID NO: 14)
    CDR3: YYYGMDY (SEQ ID NO: 15)
    The light chain CDRs of an anti-MMP9 antibody as described in this application have the following amino acid sequences:
    CDR1: KASQDVRNTVA (SEQ ID NO: 16)
    CDR2: SSSYRNT (SEQ ID NO: 17)
    CDR3: QQHYITPYT (SEQ ID ΝΟ.Ί8)
    Nucleic acids encoding anti-IVIMP9 antibodies
    The present description provides nucleic acids that encode anti-MMP9 antibodies and functional fragments thereof. Accordingly, the present description provides an isolated polynucleotide (nucleic acid) that encodes an antibody or antigen binding fragment as described in this application, vectors containing such polynucleotides, and host cells and expression systems for transcribing and translating such polynucleotides to polypeptides.
    24/36
    The present description also contemplates constructs in the form of plasmids, vectors, transcripts or expression cassettes that comprise at least one polynucleotide as above.
    The present description also provides a recombinant host cell comprising one or more constructs as above, as well as the methods of producing the antibody or antigen-binding fragments thereof described in this application, a method which comprises expression of nucleic acid encoding a polypeptide heavy chain and a light chain polypeptide (in the same or different host cells, and the same or different constructs) in a recombination host cell. Expression can be achieved by culturing recombinant host cells containing nucleic acid under appropriate conditions. Following production by expression, an antibody or antigen-binding fragment can be isolated and / or purified using any suitable technique, then used as appropriate.
    The systems for cloning and expressing a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, hamster cub kidney cells, NSO mouse melanoma cells and many others. A common bacterial host is E. coli.
    Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including operably linked promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and / or other sequences as appropriate. Vectors can be plasmids, viruses, for example, phage or phagemid, as appropriate. For further details see, for example, Molecular Cloning: A Laboratory Manual: 2nd Edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulating nucleic acid, for example, in
    25/36 preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression and protein analysis, are described in detail in Short Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. The revelations by Sambrook et al. and Ausubel et al. are incorporated in this application by reference in their entirety.
    The nucleic acid encoding a polypeptide of interest is integrated into the host cell's genome or can be maintained as a stable or transient episomal element.
    Any of a wide variety of expression control sequences - sequences that control the expression of a DNA sequence operably linked to it - can be used in these vectors to express the DNA sequences. For example, a nucleic acid encoding a polypeptide of interest can be operably linked to a promoter and provided in an expression construct for use in methods of producing recombinant MMP9 proteins or portions thereof.
    Those skilled in the art are aware that the nucleic acids encoding the antibody chains described in this application can be synthesized using standard knowledge and procedures in molecular biology.
    Examples of nucleotide sequences encoding the heavy chain amino acid sequences and light chain amino acid sequences described in this application are as follows:
    VH1: CAGGTGCAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGGAAGG GCCTGGAATG GCTGGGCGTG ATCTGGACCG GCGGCACCAC CAACTACAAC TCCGCCCTGA TGTCCCGGCT GACCATCTCC AAGGACGACT CCAAGTCCAC CGTGTACCTG AAGATGAACT CCCTGAAAAC CGAGGACACC GCCATCTACT ACTGCGCCCG GTACTACTAC GGCATGGACT ACTGGGGCCA GGGCACCTCC GTGACCC-CCTCA TGT (SEQ ID NO: 19)
    26/36
    VH2: CAGGTGCAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC
    ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGCAAAG GCCTGGAATG GCTGGGCGTG ATCTGGACCG GCGGCACCAC CAACTACAAC TCCGCCCTGA TGTCCCGGCT GACCATCTCC AAGGACGACT CCAAGAACAC CGTGTACCTG AAGATGAACT CCCTGAAAAC CGAGGACACC GCCATCTACT ACTGCGCCCG GTACTACTAC GGCATGGACT ACTGGGGCCA GGGCACCCTG GTCACCGTGT CCTCA (SEQ ID NO: 20)
    VH3: CAGGTGCAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGCAAAG GCCTGGAATG GCTGGGCGTG ATCTGGACCG GCGGCACCAC CAACTACAAC TCCGCCCTGA TGTCCCGGTT CACCATCTCC AAGGACGACT CCAAGAACAC CGTGTACCTG AAGATGAACT CCCTGAAAAC CGAGGACACC GCCATCTACT ACTGCGCCCG GTACTACTAC GGCATGGACT ACTGGGGCCA GGGCACCCTG GTCACCGTGT CCTCA (SEQIDN0: 21)
    VH4: CAGGTGCAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGCAAAG GCCTGGAATG GCTGGGCGTG ATCTGGACCG GCGGCACCAC CAACTACAAC TCCGCCCTGA TGTCCCGGTT CACCATCTCC AAGGACGACT CCAAGAACAC CCTGTACCTG AAGATGAACT CCCTGAAAAC CGAGGACACC GCCATCTACT ACTGCGCCCG GTACTACTAC GGCATGGACT ACTGGGGCCA GGGCACCCTG GTCACCGTGT CCTCA (SEQ ID NO: 22)
    Vkl: GACATCGTGA TGACCCAGTC IncorporaçõesAGCTTC CTGTCCGCCT
    CCGTGGGCGA CAGAGTGACC ATCACATGCA AGGCCTCTCA GGACGTGCGG AACACCGTGG CCTGGTATCA GCAGAAAACC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTTACCG GCTCTGGCTC CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGTACTT CTGCCAGCAG CACTACATCA CCCCCTACAC CTTCGGCGGA GGCACCAAGG TGGAAATAAA A (SEQ ID NO: 23)
    Vk2: GACATCGTGA TGACCCAGTC IncorporaçõesTCCAGC CTGTCCGCCT CTGTGGGCGA
    CAGAGTGACC ATCACATGCA AGGCCTCTCA GGACGTGCGG AACACCGTGG CCTGGTATCA GCAGAAGCCC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTTACCG GCTCTGGCTC CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGTACTT CTGCCAGCAG CACTACATCA CCCCCTACAC CTTCGGCGGA GGCACCAAGG TGGAAATAAA (SEQ ID NO: 24)
    27/36
    VK3: GACATCCAGA TGACCCAGTC CCCCTCCAGC CTGTCCGCCT CTGTGGGCGA CAGAGTGACC ATCACATGCA AGGCCTCCCA GGACGTGCGG AACACCGTGG CCTGGTATCA GCAGAAGCCC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTCTCTG GCTCTGGAAG CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGTACTT CTGCCAGCAG CACTACATCA CCCCCTACAC CTTCGGCGGA GGCACCAAGG TGGAAATAAA (SEQ ID NO: 25)
    Vk4t GACATCCAGA TGACCCAGTC CCCCTCCAGC CTGTCCGCCT CTGTGGGCGA CAGAGTGACC ATCACATGCA AGGCCTCTCA GGACGTGCGG AACACCGTGG CCTGGTATCA GCAGAAGCCC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTCTCTG GCTCTGGAAG CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGIACTA CTGCCAGCAG CACTACATCA CCCCCTACAC CTTCGGCGGA GGCACCAAGG TGGAAATAAA (SEQ ID NO: 26)
    As the structure of antibodies, including the juxtaposition of CDRs and conserved regions in the variable region, structure of conserved regions and structure of the constant regions of the heavy and light chain, is well known in the art; it is within the skill of the technique to obtain related nucleic acids that encode anti-MMP-9 antibodies. Consequently, polynucleotides comprising nucleic acid sequences having homology of at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% at any one of the nucleotide sequences described in this application are also provided. Consequently, polynucleotides comprising nucleic acid sequences having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% identity to any of the nucleotide sequences described in this application are also provided.
    Pharmaceutical compositions
    MMP9 binding proteins, as well as nucleic acid (for example, DNA or RNA) encoding MMP9 binding proteins, can be provided as a pharmaceutical composition, for example, combined with a pharmaceutically acceptable carrier or excipient. Such pharmaceutical compositions are useful, for example, for administration to a
    28/36 individual in vivo or ex vivo, and to diagnose and / or treat an individual with MMP9 binding proteins.
    Pharmaceutically acceptable vehicles are physiologically acceptable to the administered patient and retain the therapeutic properties of the antibodies or peptides with which they are administered. Pharmaceutically acceptable vehicles and their formulations are generally described, for example, in Remington 'pharmaceutical Sciences (18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA 1990). An exemplary pharmaceutical vehicle is physiological saline. Each vehicle is pharmaceutically acceptable with respect to being compatible with other ingredients of the formulation and not substantially injurious to the patient.
    Pharmaceutical compositions can be formulated to be compatible with a particular, systemic or local route of administration. Accordingly, pharmaceutical compositions include vehicles, diluents or excipients suitable for administration by various routes.
    Pharmaceutical compositions can include pharmaceutically acceptable additives. Examples of additives include, but are not limited to, a sugar such as mannitol, sorbitol, glucose, xylitol, trehalose, sorbose, sucrose, galactose, dextran, dextrose, fructose, lactose and mixtures thereof. Pharmaceutically acceptable additives can be combined with pharmaceutically acceptable vehicles and / or excipients such as dextrose. Additives also include surfactants such as polysorbate 20 or polysorbate 80.
    The formulation and delivery methods will generally be adapted according to the site and the disease to be treated. Exemplary formulations include, but are not limited to, those suitable for parenteral administration, for example, intravenous, intraarterial, intramuscular or subcutaneous administration.
    Pharmaceutical compositions for parenteral delivery include, for example, water, saline, phosphate-buffered saline, Hank's solution, Ringer's solution, dextrose / saline and glucose solutions. The formulations can contain auxiliary substances to approach physiological conditions, such as buffering agents, tonicity adjusting agents, humidifying agents, detergents and the like. Additives can also include additional active ingredients such as bactericidal or stabilizing agents. For example, the solution may contain sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate. Parenteral formulations and additional methods are described in Bai (1997) J. Neuroimmunol. 80:65 75; Warren (1997) J. Neurol. Know. 152: 31 38; and Tonegawa (1997) J. Exp. Med. 186: 507 515. The parenteral preparation can be enclosed in ampoules, disposable syringes or multi-dose vials made of glass or plastic.
    Pharmaceutical compositions for intradermal or subeutaneous administration may include a sterile diluent, such as water, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid, glutathione or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and tonicity adjusting agents such as sodium chloride or dextrose.
    Pharmaceutical compositions of injection include aqueous solutions (where water soluble) or dispersions and sterile powders for extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable vehicles include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, liquid glycerol, propylene glycol and polyethylene glycol, and the like), and suitable mixtures thereof. Fluidity can be maintained, for example, by using a coating like lecithin, by maintaining the required particle size in case of dispersion and by using surfactants. Antibacterial and antifungal agents include, for example, parabens, chlorobutanol, phenol, ascorbic acid and thimerosal. Isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol and sodium chloride can be included in the composition. The resulting solutions can be packaged for use as es30 / 36 so, or lyophilized; the lyophilized preparation can then be combined with a sterile solution before administration.
    Pharmaceutically acceptable vehicles may contain a compound that stabilizes, increases or delays absorption or clearance. Such compounds include, for example, carbohydrates, such as glucose, sucrose or dextrans; low molecular weight proteins; compositions that reduce peptide clearance or hydrolysis; or excipients or other stabilizers and / or buffers. Absorption-delaying agents include, for example, aluminum monostearate and gelatin. Detergents can also be used to stabilize or increase or reduce the absorption of the pharmaceutical composition, including liposomal vehicles. To protect from digestion, the compound can be complexed with a composition to make it resistant to acidic and enzymatic hydrolysis, or the compound can be complexed in an appropriately resistant vehicle such as a liposome. Protections for digestion compounds are known in the art (see, for example, Fix (1996) Pharm Res. 13: 1760 1764; Samanen (1996) J. Pharm. Pharmacol. 48: 119 135; and U.S. Pat. No. 5,391,377, describing lipid compositions for oral delivery of therapeutic agents).
    Compositions of the present invention can be combined with other therapeutic portions or imaging portions / diagnostic portions provided in this application. Therapeutic portions and / or imaging portions can be provided as a separate composition, or as a portion of the conjugate present in an MMP9-binding protein.
    Formulations for in vivo administration are generally sterile. In one embodiment, pharmaceutical compositions are formulated to be pyrogen-free such that they are acceptable for administration to human patients.
    Various other pharmaceutical compositions and techniques for their preparation and use are known to those skilled in the art in light of the present description. For a detailed listing of suitable pharmacological compositions and associated administrative techniques, refer to the teachings detailed in this application, which can be further supplemented by texts such as Remington: The Science and Practice of Pharmacy 20th Ed. (Lippincott, Williams & Wilkins 2003).
    The pharmaceutical compositions can be formulated based on the physical characteristics of the patient / individual in need of treatment, the route of administration, and the like. This can be packaged in a suitable pharmaceutical package with appropriate labels for distribution to hospitals and clinics where the label is for the indication of treatment of a disorder as described in this application in an individual. Medicines can be packaged as single or multiple units. Dosage instructions and administration of the pharmaceutical compositions of the present invention can be included with the pharmaceutical packages and kits described below.
    Usage methods
    The MMP9 binding proteins of the present description can be used, for example, in methods of detecting MMP9 in a sample, methods of treatment (for example, as in methods of inhibiting angiogenesis) and methods of diagnosis. Examples of methods of use are described below.
    Treatment methods
    Methods of treating diseases and disorders associated with MMP9 activity are provided in this application. Diseases and disorders include, but are not limited to, tumors (for example, primary or metastatic) that express or are arranged in a tissue expressing MMP9.
    As used in this application, treating or treating means stasis or delaying the development of symptoms associated with a disease or disorder described in this application. The terms further include improving existing, uncontrolled or unwanted symptoms, preventing additional symptoms, and improving or preventing the underlying metabolic causes of symptoms. Thus, the terms denote that a beneficial result was conferred on a mammalian individual with a disease or symptom, or with the potential to fall ill from such a disease or symptom. A response is achieved when the patient experiences partial or total relief, or reduction of signs or symptoms of the disease, and specifically includes, without limitation, prolonged survival. The expected survival times without progressions can be measured for many months to years, depending on prognostic factors including the number of relapses, the stage of the disease and other factors.
    The present description contemplates pharmaceutical compositions for use in connection with such methods. The compositions can be suitable for administration locally or systemically by any suitable route.
    In general, MMP9 binding proteins are administered in a therapeutically effective amount, for example, in an amount to effect inhibition of tumor growth in an individual and / or to inhibit metastasis.
    As used in this application, the term therapeutically effective amount or effective amount refers to an amount of a therapeutic agent that when administered alone or in combination with another therapeutic agent to an individual is effective in preventing or ameliorating the condition of the disease or progression of the disease. disease. A therapeutically effective dose further refers to that amount of the compound sufficient to result in improvement of symptoms, for example, treatment, cure, prevention or amelioration of the relevant disease or an increase in the rate of treatment, cure, prevention or amelioration of such conditions. When applied to an individual active ingredient administered alone, a therapeutically effective dose refers to that ingredient alone. When a combination is applied, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, in series or simultaneously. For example, when in vivo administration of an anti-MMP9 antibody is employed, normal dosage amounts can range from approximately 10 ng / kg to up to 100 mg / kg of mammalian body weight or more per day, preferably approximately 1 pg / kg / day at 50 mg / kg / day, optionally approximately 100 pg / kg / day at 20 mg / kg / day, 500 pg / kg / day at 10 mg / kg / day or 1 mg / kg / day at 10
    33/36 mg / kg / day, depending on the route of administration.
    The dosage regimen selected will depend on a variety of factors including the activity of the MMP9-binding protein, the route of administration, the time of administration, the rate of excretion of the particular compound that is employed, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular composition employed, the age, sex, weight, condition, general health and previous medical history of the patient being treated, and as factors well known in medical techniques.
    A clinician having ordinary skill in the art can readily determine and prescribe the effective amount (ED50) of the required pharmaceutical composition. For example, the doctor or veterinarian may start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that necessary in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
    As used in this application, the term individual means mammalian individuals. Exemplary individuals include, but are not limited to, humans, monkeys, dogs, cats, mice, rats, cows, horses, goats and sheep. In some embodiments, the individual has cancer and can be treated with the agent of the present invention as described below.
    If necessary, for cancer treatments, the methods may also include surgical removal of the cancer and / or administration of an anti-cancer agent or treatment in addition to an MMP-binding protein9. The administration of such an anticancer agent or treatment can be simultaneous with the administration of the compositions described in this application.
    Detection methods of MMP9
    The present description also contemplates methods of detecting MMP9 in an individual, for example, detecting tumor or tumor-associated tissue expressing MMP9. Thus, methods of diagnosis, monitoring, staging or detecting a tumor having MMP9 activity are provided.
    34/36
    Samples from an individual suspected of having a tumor associated with MMP9 expression can be collected and analyzed for the presence or absence of binding of an MMP9 binding protein. This analysis can be performed prior to initiation of treatment using an MMP9-binding protein as described in this application or can be done as part of monitoring the progress of cancer treatment. Such diagnostic analysis can be performed using any sample, including but not limited to tissue, cells isolated from such tissues, and the like. Tissue samples include, for example, sections of tissue fixed in formalin or frozen.
    Any suitable method for detection and analysis of MMP9 can be employed. Various diagnostic assay techniques known in the art can be adapted for this purpose, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in heterogeneous or homogeneous phases.
    MMP9-binding proteins for use in detection methods can be labeled with a detectable portion. The directly or indirectly detectable portion produces a detectable signal. For example, the detectable portion can be any of those described in this application such as, for example, a radioisotope, such as 3H, 14C, 32P, 35S, or 1251, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate (FITC), Texas Red, cyanine, photocyanine, rhodamine, or luciferin or an enzyme such as alkaline phosphatase, β-galactosidase or horseradish peroxidase.
    Detection can be performed by contact with a sample under conditions suitable for MMP9-binding protein that binds to MMP9 and assesses the presence (eg, level) or absence of MMP9-MMP9-binding protein complexes. A level of MMP9 in the sample compared to a level in a reference sample can indicate the presence of a tumor or tissues associated with the tumor having MMP9 activity. The reference sample can be a sample taken from the individual at an earlier time point or a sample from another individual.
    35/36
    EXAMPLES
    Example 1: Preparation of antibodies to human MMP-9.
    The entire human MMP9 protein without a signal peptide, which is SEQ ID NO. 28, was used to immunize mice. Spleen cells from immunized mice were fused with myeloma cells to generate a hybridoma library. Monoclonal cultures were prepared and screened to identify cultures that express an anti-MMP9 monoclonal antibody.
    The antibody (AB0041) was purified from one of the cultures and characterized. The antibody contained an IgG2b heavy chain and a kappa light chain. Characterization included the test for binding AB0041 to other human MMPs and to MMP9 proteins of other species, including cynomolgus monkey, rat and mouse. It was found that the AB0041 antibody bound strongly to human and cinomolgus MMP9, which bound less strongly to rat MMP9, and which did not bind to murine MMP9 or many of the human non-MMP matrix metalloproteinases.
    Table 2. Cross reactivity of AB0041 and AB0045.
    MMP Tested Dissociation constant (Kd) AB0045 AB0041 Human MMP1 > 100 nM > 100 nM Human MMP2 > 100 nM > 100 nM Mouse MMP2 > 100 nM > 100 nM Human MMP3 > 100 nM > 100 nM Human MMP7 > 100 nM > 100 nM Human MMP8 > 100 nM > 100 nM Human MMP9 0.168 ± 0.117 nM 0.133 ± 0.030 nM Cinomolgus Monkey MMP9 0.082 ± 0.022 nM 0.145 ± 0.16 nM Mouse MMP9 > 100 nM > 100 nM Mouse MMP9 0.311 ± 0.017 nM 0.332 ± 0.022 nM Human MMP10 > 100 nM > 100 nM Human MMP12 > 100 nM > 100 nM Human MMP13 > 100 nM > 100 nM
    36/36
    Additional characterization included analyzing the binding of the antibody to mouse MMP9 in which certain amino acids were altered to more closely match the human MMP9 sequence. In addition, the human MMP9 protein has been mutagenized and several mutants tested for its ability to be bound by the antibody, determine amino acids important for antibody binding and thereby define the therapeutic epitope. This analysis identified an arginine residue at position 162 of the MMP9 amino acid sequence (R162) as important for antibody binding. Other amino acid residues in MMP9 that are important for binding the AB0041 antibody include E111, D113 and 1198. The recent crystal structure of MMP9 showed that E111, D113, R162 and 1198 were clustered close together around an ion binding pouch Ca 2+ to MMP9. Without being linked to any specific scientific theory, AB0041 can link to the region in MMP9 where these residues are located. Alternatively, these MMP9 residues can have direct contact with AB0041.
    In an enzymatic assay for MMP9, it was discovered that the AB0041 antibody acted as a non-competitive inhibitor.
    Example 2: Humanization of antibodies to human MMP9
    The amino acid sequences of the heavy chain and the light chain of the mouse AB0041 antibody have been altered at certain positions in the portion of the conserved (i.e., non-CDR) region of their variable regions to generate proteins that are less immunogenic in humans. These amino acid sequence modifications were shown in Figures 1 and 2. The cross-reactivity of the humanized antibody (referred to as AB0045) is shown in Table 2 above.
    权利要求:
    Claims (13)
    [1]
    1. Monoclonal antibody or antigen-binding fragment thereof, characterized by the fact that it comprises a heavy chain polypeptide comprising CDRs of SEQ ID NOs: 13-15 and a light chain polypeptide comprising CDRs of SEQ ID NOs: 16-18 , wherein the antibody or antigen-binding fragment thereof specifically binds MMP9.
    [2]
    2. Monoclonal antibody or antigen-binding fragment thereof, according to claim 1, characterized by the fact that the heavy chain polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-8 and / or the light chain polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-12.
    [3]
    A monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that the heavy chain polypeptide comprises an amino acid sequence of SEQ ID NO: 3 and / or the light chain polypeptide comprises a amino acid sequence of SEQ ID NO: 4.
    [4]
    4. Monoclonal antibody or antigen-binding fragment thereof, according to claim 1 or 2, characterized in that the heavy chain polypeptide comprises an amino acid sequence of SEQ ID NO: 7 and / or the chain polypeptide light comprises an amino acid sequence of SEQ ID NO: 12.
    [5]
    A monoclonal antibody or antigen-binding fragment thereof, according to any one of claims 1 to 4, characterized in that the antibody or antigen-binding fragment thereof is a humanized or chimeric antibody.
    [6]
    6. Isolated nucleic acid, characterized by the fact that it comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-26.
    [7]
    7. Vector, characterized by the fact that it contains the original sequence for replication, selection marker sequence, and multiple sites of
    Petition 870180167211, of 12/24/2018, p. 13/52
    2/2 cloning, characterized by the fact that it comprises a nucleotide sequence selected from the group consisting of SEQ ID Nos: 19-26.
    [8]
    8. Transgenic microorganism, characterized by the fact that it comprises the vector as defined in claim 7.
    [9]
    Pharmaceutical composition, characterized in that it comprises the monoclonal antibody or antigen-binding fragment thereof as defined in any one of claims 1 to 5, and a pharmaceutically acceptable carrier.
    [10]
    10. Pharmaceutical composition, characterized by the fact that it comprises the vector as defined in claim 7, and a pharmaceutically acceptable carrier.
    [11]
    11. Pharmaceutical composition, characterized by the fact that it comprises the transgenic microorganism as defined in claim 8, and a pharmaceutically acceptable carrier.
    [12]
    12. Method of detecting the expression of MMP9 in a patient's tissue, characterized by the fact that it comprises:
    contacting a patient's tissue sample with a monoclonal antibody or antigen-binding fragment thereof as defined in any one of claims 1 to 5; and detecting the presence or absence of MMP9;
    wherein the presence of MMP9 in the tissue sample indicates that MMP9 is expressed in the tissue.
    [13]
    13. Use of the pharmaceutical composition as defined in claim 9, characterized in that it is in the preparation of a drug to inhibit the activity of MMP9 in an individual having a tumor or tissue associated with the tumor having activity of MMP9, in which the drug is to be administered in an amount effective to inhibit MMP9 activity; and where MMP9 activity is inhibited in the individual.
    类似技术:
    公开号 | 公开日 | 专利标题
    US20180086845A1|2018-03-29|Nucleic acids encoding antibodies to matrix metalloproteinase 9
    AU2017216508B2|2019-03-07|Antibodies to matrix metalloproteinase 9
    AU2015201367B2|2016-12-15|Antibodies to matrix metalloproteinase 9
    OA18526A|2018-12-14|Antibodies to Matrix Metalloproteinase 9
    NZ629888B2|2017-05-25|Antibodies to matrix metalloproteinase 9
    同族专利:
    公开号 | 公开日
    CN103140240B|2015-01-21|
    JP6198797B2|2017-09-20|
    KR101518144B1|2015-05-28|
    US8377443B2|2013-02-19|
    KR20180014245A|2018-02-07|
    CN103140240A|2013-06-05|
    US20130281676A1|2013-10-24|
    MX342413B|2016-09-28|
    US20130023654A1|2013-01-24|
    AU2011293125B2|2015-02-05|
    ES2739505T3|2020-01-31|
    CN104530238B|2019-11-26|
    NZ606880A|2015-01-30|
    US20160159923A1|2016-06-09|
    IL224614A|2017-11-30|
    CO6680656A2|2013-05-31|
    UA109908C2|2015-10-26|
    PL2608809T3|2019-10-31|
    WO2012027721A2|2012-03-01|
    JP2016020389A|2016-02-04|
    CA2808418A1|2012-03-01|
    US20120135004A1|2012-05-31|
    CN104530238A|2015-04-22|
    IL255300D0|2017-12-31|
    KR101881724B1|2018-07-24|
    EP2608809B1|2019-05-22|
    US20160122437A1|2016-05-05|
    SG10201506703VA|2015-10-29|
    US9260532B2|2016-02-16|
    PE20131376A1|2013-11-25|
    CA2808418C|2019-02-05|
    BR112013004579A2|2016-02-10|
    PT2608809T|2019-08-26|
    JP6435381B2|2018-12-05|
    MA34527B1|2013-09-02|
    SI2608809T1|2019-08-30|
    KR101930179B1|2018-12-17|
    US20180086845A1|2018-03-29|
    ECSP13012525A|2013-05-31|
    WO2012027721A3|2012-08-16|
    US9120863B2|2015-09-01|
    US20130281675A1|2013-10-24|
    JP2017221216A|2017-12-21|
    AP2016009448A0|2016-09-30|
    KR101827048B1|2018-02-07|
    EA201390146A1|2013-12-30|
    SG188224A1|2013-04-30|
    US8501916B2|2013-08-06|
    AU2011293125A1|2013-04-18|
    ZA201301338B|2016-07-27|
    EP2608809A4|2015-04-01|
    KR20130063009A|2013-06-13|
    CR20130132A|2013-05-29|
    KR20170030659A|2017-03-17|
    MX2013002323A|2013-07-29|
    TR201910348T4|2019-08-21|
    JP5878538B2|2016-03-08|
    KR20150004936A|2015-01-13|
    NZ701444A|2016-06-24|
    EA031729B1|2019-02-28|
    PH12016501691A1|2017-07-03|
    HK1208688A1|2016-03-11|
    EP2608809A2|2013-07-03|
    AP3948A|2016-12-21|
    CL2013000535A1|2014-03-21|
    JP2013539365A|2013-10-24|
    ZA201507081B|2017-02-22|
    AP2013006743A0|2013-02-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4816567A|1983-04-08|1989-03-28|Genentech, Inc.|Recombinant immunoglobin preparations|
    GB8823869D0|1988-10-12|1988-11-16|Medical Res Council|Production of antibodies|
    DE3920358A1|1989-06-22|1991-01-17|Behringwerke Ag|BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE|
    US5633425A|1990-08-29|1997-05-27|Genpharm International, Inc.|Transgenic non-human animals capable of producing heterologous antibodies|
    US5661016A|1990-08-29|1997-08-26|Genpharm International Inc.|Transgenic non-human animals capable of producing heterologous antibodies of various isotypes|
    US5545806A|1990-08-29|1996-08-13|Genpharm International, Inc.|Ransgenic non-human animals for producing heterologous antibodies|
    US5625126A|1990-08-29|1997-04-29|Genpharm International, Inc.|Transgenic non-human animals for producing heterologous antibodies|
    CA2089661C|1990-08-29|2007-04-03|Nils Lonberg|Transgenic non-human animals capable of producing heterologous antibodies|
    GB9022788D0|1990-10-19|1990-12-05|Cortecs Ltd|Pharmaceutical formulations|
    EP0617706B1|1991-11-25|2001-10-17|Enzon, Inc.|Multivalent antigen-binding proteins|
    WO1995015374A1|1993-11-30|1995-06-08|Fuji Yakuhin Kogyo Kabushiki Kaisha|Novel metalloprotease and dna coding for the same|
    US5612030A|1995-01-17|1997-03-18|University Of Kentucky Research Foundation|Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma|
    EP1085882A2|1998-06-05|2001-03-28|Mayo Foundation For Medical Education And Research|Use of genetically engineered antibodies to cd38 to treat multiple myeloma|
    US7101975B1|1999-07-13|2006-09-05|University Of Southern California|Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins|
    AT435031T|1999-07-13|2009-07-15|Univ Southern California|METHOD AND COMPOSITION FOR ANGIOGENESIS INHIBITION WITH ANTAGONISTS AGAINST MMP-9 AND BETA1 INTEGRINS|
    WO2002066057A2|2001-02-23|2002-08-29|Biophage Inc.|Methods and compositions for preventing and treating neutrophil-mediated diseases|
    SE0102298D0|2001-06-27|2001-06-27|Astrazeneca Ab|Crystal structure of enzyme and uses thereof|
    US20030139332A1|2001-07-09|2003-07-24|The Regents Of The University Of California|Use of matrix metalloproteinase inhibitors to mitigate nerve damage|
    WO2003044058A2|2001-11-23|2003-05-30|Universite Catholique De Louvain|Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis|
    EP1545611B1|2002-09-06|2016-11-09|Alexion Pharmaceuticals, Inc.|Method of treatment of asthma using antibodies to complement component c5|
    WO2004076614A2|2003-02-27|2004-09-10|Bernd Hinzmann|Human nucleic acid sequences obtained from prostatic carcinomas|
    WO2004087042A2|2003-04-04|2004-10-14|Yeda Research And Development Co. Ltd.|Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins|
    WO2006037513A1|2004-10-09|2006-04-13|Bayer Healthcare Ag|Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 |
    CN101268369A|2005-06-29|2008-09-17|儒勒斯贝斯特医药有限公司|Methods and kits for the diagnosis of acute coronary syndrome|
    US8957187B2|2005-12-02|2015-02-17|Genentech, Inc.|Binding polypeptides and uses thereof|
    WO2007144781A2|2006-04-21|2007-12-21|Diagnotech Pty. Ltd.|Diagnostic methods and kits utilizing antibodies for metalloproteases|
    WO2008088864A2|2007-01-18|2008-07-24|The Trustess Of Columbia University In The City Of New York|Matrix metalloproteinase-9-related methods|
    CA2678304A1|2007-02-23|2008-08-28|Yeda Research And Development Co. Ltd.|Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins|
    AR066913A1|2007-06-08|2009-09-23|Irm Llc|METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS|
    CA2695969A1|2007-08-15|2009-02-19|Yeda Research & Development Co. Ltd.|Regulators of mmp-9 and uses therof|
    EP2231186A4|2007-12-17|2012-08-08|Dyax Corp|Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins|
    US8013125B2|2008-03-03|2011-09-06|Dyax Corp.|Metalloproteinase 9 and metalloproteinase 2 binding proteins|
    AU2009222048A1|2008-03-03|2009-09-11|Dyax Corp.|Metalloproteinase 9 binding proteins|
    WO2010048432A1|2008-10-22|2010-04-29|Dyax Corp.|Combination treatments comprising protease binding proteins for inflammatory disorders|
    US20110286916A1|2008-11-20|2011-11-24|Jose Miguel Aste-Amezaga|Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use|
    EA201270701A1|2010-01-27|2013-01-30|Йеда Рисеч Энд Девелопмент Ко. Лтд.|INHIBITING METAL PROTEINS ANTIBODIES|
    US20110261695A1|2010-04-23|2011-10-27|Xiaoming Zhao|System and method for network congestion control|
    PE20131376A1|2010-08-27|2013-11-25|Gilead Biologics Inc|ANTIBODIES TO MATRIX METALOPROTEINASE-9|
    CA2865501A1|2012-02-29|2013-09-06|Gilead Biologics, Inc.|Antibodies to matrix metalloproteinase 9|
    WO2013130078A1|2012-02-29|2013-09-06|Gilead Biologics, Inc.|Antibodies to matrix metalloproteinase 9|PE20131376A1|2010-08-27|2013-11-25|Gilead Biologics Inc|ANTIBODIES TO MATRIX METALOPROTEINASE-9|
    EP3252076B1|2011-01-14|2019-09-04|The Regents Of The University Of California|Diagnostic use of antibodies against ror-1 protein|
    WO2013130078A1|2012-02-29|2013-09-06|Gilead Biologics, Inc.|Antibodies to matrix metalloproteinase 9|
    CA2865501A1|2012-02-29|2013-09-06|Gilead Biologics, Inc.|Antibodies to matrix metalloproteinase 9|
    CN105246500A|2013-04-05|2016-01-13|克劳迪娅·齐尔贝尔博格|Matrix metalloproteinases and uses thereof|
    JP2016537433A|2013-11-26|2016-12-01|ギリアード サイエンシーズ， インコーポレイテッド|Therapies to treat myeloproliferative disorders|
    WO2015109286A1|2014-01-20|2015-07-23|Gilead Sciences, Inc.|Therapies for treating cancers|
    EP2985295A1|2014-08-13|2016-02-17|Calypso Biotech SA|Antibodies specific for MMP9|
    EP2985296A1|2014-08-13|2016-02-17|Calypso Biotech SA|Antibodies specific for MMP9|
    TW201639573A|2015-02-03|2016-11-16|吉李德科學股份有限公司|Combination therapies for treating cancers|
    SG11201606876RA|2015-03-04|2016-10-28|Gilead Sciences Inc|Toll like receptor modulator compounds|
    CN105037553B|2015-08-20|2018-04-17|内蒙古蒙元生物基因科技有限公司|A kind of immunoglobulin that can detect cancer|
    WO2017059224A2|2015-10-01|2017-04-06|Gilead Sciences, Inc.|Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers|
    WO2017106566A1|2015-12-17|2017-06-22|Gilead Sciences, Inc.|Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders|
    PE20181073A1|2015-12-17|2018-07-04|Gilead Sciences Inc|TANK BINDING KINASE INHIBITING COMPOUNDS|
    EP3423057A1|2016-03-04|2019-01-09|Gilead Sciences, Inc.|Compositions and combinations of autotaxin inhibitors|
    WO2017177179A1|2016-04-08|2017-10-12|Gilead Sciences, Inc.|Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases|
    CA3032813A1|2016-08-04|2018-02-08|Gilead Sciences, Inc.|Cobicistat for use in cancer treatments|
    US10370342B2|2016-09-02|2019-08-06|Gilead Sciences, Inc.|Toll like receptor modulator compounds|
    EP3507288B1|2016-09-02|2020-08-26|Gilead Sciences, Inc.|4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators|
    US20180133212A1|2016-11-03|2018-05-17|Gilead Sciences, Inc.|Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer|
    US20180141939A1|2016-11-22|2018-05-24|Gilead Sciences, Inc.|Solid forms of a bet inhibitor|
    CN110312737A|2016-12-16|2019-10-08|波尔多大学|MMP9 inhibitor and its purposes in prevention or treatment depigmentation illness|
    JP2020515508A|2017-01-24|2020-05-28|アイ−エムエービー バイオファーマ ユーエス リミテッド|Anti-CD73 antibody and use thereof|
    AR110998A1|2017-02-24|2019-05-22|Gilead Sciences Inc|INHIBITORS OF THE TUTOSINA CINASA DE BRUTON|
    EP3585789A1|2017-02-24|2020-01-01|Gilead Sciences, Inc.|Inhibitors of bruton's tyrosine kinase|
    US10941178B2|2017-03-17|2021-03-09|Gilead Sciences, Inc.|Method of purifying an antibody|
    JOP20180040A1|2017-04-20|2019-01-30|Gilead Sciences Inc|Pd-1/pd-l1 inhibitors|
    CN111051339A|2017-07-18|2020-04-21|第一三共株式会社|Active MMP-9-binding peptides|
    US11203610B2|2017-12-20|2021-12-21|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|
    US10966999B2|2017-12-20|2021-04-06|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|
    TWI707849B|2018-02-13|2020-10-21|美商基利科學股份有限公司|Pd-1/pd-l1 inhibitors|
    TW202010503A|2018-04-06|2020-03-16|捷克科學院有機化學與生物化學研究所|3’3’－cyclic dinucleotides|
    TW202005655A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'3'-cyclic dinucleotides|
    TW202005654A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'2'-cyclic dinucleotides|
    US10899735B2|2018-04-19|2021-01-26|Gilead Sciences, Inc.|PD-1/PD-L1 inhibitors|
    TW202014193A|2018-05-03|2020-04-16|捷克科學院有機化學與生物化學研究所|2’3’-cyclic dinucleotides comprising carbocyclic nucleotide|
    CN112118845A|2018-05-14|2020-12-22|吉利德科学公司|MCL-1 inhibitors|
    CA3103286A1|2018-07-13|2020-01-16|Gilead Sciences, Inc.|Pd-1/pd-l1 inhibitors|
    EP3860717A1|2018-10-03|2021-08-11|Gilead Sciences, Inc.|Imidozopyrimidine derivatives|
    WO2020086556A1|2018-10-24|2020-04-30|Gilead Sciences, Inc.|Pd-1/pd-l1 inhibitors|
    CR20210215A|2018-10-31|2021-06-17|Gilead Sciences Inc|Substituted 6-azabenzimidazole compounds as hpk1 inhibitors|
    EP3873608A1|2018-10-31|2021-09-08|Gilead Sciences, Inc.|Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity|
    WO2020178770A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotides and prodrugs thereof|
    WO2020178768A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator|
    WO2020178769A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2'3'-cyclic dinucleotides and prodrugs thereof|
    WO2020214663A1|2019-04-17|2020-10-22|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|
    EP3956329A1|2019-04-17|2022-02-23|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|
    WO2020237025A1|2019-05-23|2020-11-26|Gilead Sciences, Inc.|Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors|
    WO2020255038A1|2019-06-18|2020-12-24|Janssen Sciences Ireland Unlimited Company|Combination of hepatitis b virusvaccines and pyridopyrimidine derivatives|
    CA3142513A1|2019-06-25|2020-12-30|Gilead Sciences, Inc.|Flt3l-fc fusion proteins and methods of use|
    WO2021076908A1|2019-10-18|2021-04-22|Forty Seven, Inc.|Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia|
    WO2021087064A1|2019-10-31|2021-05-06|Forty Seven, Inc.|Anti-cd47 and anti-cd20 based treatment of blood cancer|
    TW202128714A|2019-11-12|2021-08-01|美商基利科學股份有限公司|Mcl1 inhibitors|
    WO2021130638A1|2019-12-24|2021-07-01|Carna Biosciences, Inc.|Diacylglycerol kinase modulating compounds|
    WO2021163064A2|2020-02-14|2021-08-19|Jounce Therapeutics, Inc.|Antibodies and fusion proteins that bind to ccr8 and uses thereof|
    WO2021222522A1|2020-05-01|2021-11-04|Gilead Sciences, Inc.|Cd73 inhibiting 2,4-dioxopyrimidine compounds|
    法律状态:
    2016-05-24| B65X| Notification of requirement for priority examination of patent application|
    2016-06-28| B65Y| Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)|
    2016-09-13| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2017-10-31| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2018-05-15| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|
    2018-09-25| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|
    2019-02-12| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2019-03-12| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2011, OBSERVADAS AS CONDICOES LEGAIS. |
    2021-08-10| B21F| Lapse acc. art. 78, item iv - on non-payment of the annual fees in time|Free format text: REFERENTE A 10A ANUIDADE. |
    2021-11-30| B24J| Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)|Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
    优先权:
    申请号 | 申请日 | 专利标题
    US37788610P| true| 2010-08-27|2010-08-27|
    US61/377,886|2010-08-27|
    PCT/US2011/049448|WO2012027721A2|2010-08-27|2011-08-26|Antibodies to matrix metalloproteinase 9|
    [返回顶部]